Pelubiprofen was also non-inferior to celecoxib in terms of the secondary end points , such as , decrease in KHAQ score ( @ @ , @ % CI -@ to ) , decrease in duration of morning stiffness ( median @ minute in both groups ) , and decrease in the frequency ( @ @ , @ % CI -@ to ) and total amount ( @ @ , @ % CI -@ to ) of rescue medication uses during the @ week study period .